Opportunities
Search

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-05

Buyer: Trafikverket Myndighet | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-06

Buyer: Ystad Kommun | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-06

Buyer: Varuförsörjningen | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-06

Buyer: Varuförsörjningen | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-06

Buyer: FMV | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-06

Buyer: Direção Regional das Obras Públicas | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-06

Buyer: Kainuun hyvinvointialue | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-09-06

Buyer: Trafikverket Myndighet | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-06

Buyer: Trafikverket Myndighet | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-09-06

Buyer: AB „Kelių priežiūra“ | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-09-06

This Funding Opportunity Announcement (FOA) encourages grant applications for Biomedical Technology Resource Centers (BTRCs). BTRCs are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. BTRCs also make their technologies available to other investigators, train members of the research community in the use of the technologies, and disseminate the technologies broadly.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects.

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. With this NOFO, the NCI intends to encourage submission of projects devoted to demonstrating that mammalian models or their derivatives used for translational research are robust representations of human biology, are appropriate to test questions of clinical importance, and provide reliable information for patients' benefit. These practical goals contrast with the goals of many mechanistic, NCI-supported R01 projects that employ mammals, or develop and use mammalian cancer models, transplantation tumor models, or models derived from mammalian or human tissues or cells for hypothesis-testing, non-clinical research. Among many other possible endeavors, applicants in response to this FOA could propose demonstrations of how to overcome translational deficiencies of mammalian oncology models, define new uses of mammalian models or their genetics for unexplored translational challenges, advance standard practices for use of translational models, test approaches to validate and credential models, or challenge current practices for how models are used translationally

This Notice of Funding Opportunity (NOFO) encourages research on the biology of high confidence risk factors associated with complex brain disorders, with a focus on the intracellular, transcellular and circuit substrates of neural function. For the purposes of this NOFO, the term complex can refer to a multifactorial contribution to risk (e.g., polygenic and/or environmental) and/or highly distributed functional features of the brain disorder. Studies may be either hypothesis-generating (unbiased discovery) or hypothesis-testing in design and may utilize in vivo, in situ, or in vitro experimental paradigms, e.g., model organisms or human cell-based assays. While behavioral paradigms and outcome measures can be incorporated into the research design to facilitate the characterization of intracellular, transcellular and circuit mechanisms, these are neither required nor expected. Studies should not attempt to model disorders but instead should aim to elucidate the neurobiological impact of individual or combined risk factor(s), such as the affected molecular and cellular components and their relationships within defined biological process(es). This can include the fundamental biology of these factors, components and processes. The resulting paradigms, component pathways and biological processes should be disseminated with sufficient detail to enrich common and/or federated data resources (e.g., those contributing to the Gene Ontology, Synaptic Gene Ontology, FAIR Data Informatics) in order to bridge the gap between disease risk factors, biological mechanism and therapeutic ta...